−Removed: The following table summarizes our principal properties leased as of December 31, 2020:
−Removed: Principal Properties Leased:
−Removed: Lease Expiration Dates
−Removed: San Diego, California
−Removed: Laboratory - Research, Office
−Removed: El Segundo, California*
−Removed: Laboratory - Research & Manufacturing
−Removed: Culver City, California*
+Added: We lease property in multiple facilities across the U.S.
+Added: and Italy, including facilities located in El Segundo and Culver City, CA that are leased from related parties.
+Added: See Note 8 , Related-Party Agreements , of the “Notes to Consolidated Financial Statements” that appears in Part II, Item 8.
+Added: “Financial Statements and Supplementary Data” of this Annual Report for additional information about our related-party leases.
+Added: The following table summarizes our principal properties under lease as of December 31, 2021:
+Added: Location Expiration
+Added: Year (1) Approximate
+Added: Square Feet (2) Primary Function(s)
+Added: United States
+Added: El Segundo, CA 2023 - 2028
168,570 Laboratory - Research & Manufacturing
−Removed: December 2021
−Removed: Woburn, Massachusetts
+Added: Louisville, CO 2025 50,838 Laboratory - Research & Manufacturing
+Added: San Diego, CA 2023 44,681 Laboratory - Research & Corporate Office
+Added: Culver City, CA Month to Month 9,500 Laboratory - Research & Manufacturing
+Added: Woburn, MA 2025 8,153 Laboratory - Research & Office
+Added: Seattle, WA 2025 5,527 Laboratory - Research
+Added: Miramar, FL 2025 2,571 Clinical Affairs & Office
+Added: International
+Added: Italy 2024 - 2027
11,313 Laboratory - Research & Office
−Removed: El Segundo, California*
−Removed: Laboratory - Research & Manufacturing
−Removed: Torrance, California**
−Removed: Laboratory - Research
−Removed: * Property leased from a related party.
−Removed: ** Represents square footage dedicated to us within the facility, however, the lease also permits
−Removed: our non-exclusive use of the third party's vivarium premises.
−Removed: The following table summarizes our principal property owned as of December 31, 2020:
−Removed: Principal Property Owned:
−Removed: El Segundo, California
−Removed: Distribution Warehouse
−Removed: For additional information, see Note 9, Commitments and Contingencies, Contractual Obligations – Leases , and Note 10, Related Party Agreements , of the “Notes to Consolidated Financial Statements” included in Part II, Item 8 of this Annual Report.
+Added: _______________
+Added: (1) Expiration years shown are per the lease agreements in effect as of December 31, 2021 and do not reflect contractual options to extend the term of the lease available to us under the lease agreements.
+Added: For locations with multiple leases, the first and last expiration year are shown.
+Added: (2) Amounts shown represent the total approximate rentable square feet for all buildings located in each city.
+Added: On February 14, 2022, we acquired a leasehold interest in approximately 409,000 rentable square feet of cGMP ISO Class 5 pharmaceutical manufacturing space in western New York (the Dunkirk Facility).
+Added: This facility provides us with a state-of-the-art biotech production center that substantially expands and diversifies our existing manufacturing capacity in the U.S.
+Added: See Note 13 , Subsequent Events , of the “Notes to Consolidated Financial Statements” that appears in Part II, Item 8.
+Added: “Financial Statements and Supplementary Data” of this Annual Report.
+Added: We believe that our existing facilities are adequate to meet our current and future needs and that we will be able to renew existing leases and obtain additional commercial space as needed.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.